

More insurance plans than ever are offering Taltz as the Preferred IL-17A antagonist across Commercial and Part D.¹

taltz[®]
(ixekizumab)
injection
80 mg/mL

Commercial Plan	Taltz in PsO
Express Scripts [®] National Preferred Formulary	Exclusive IL-17A antagonist
Cigna [®] Commercial	Preferred IL-17A antagonist
CVS Caremark [®] Advanced Control Specialty Formulary	Preferred IL-17A antagonist
OptumRx [®] Premium and Select Formularies	Preferred IL-17A antagonist

Part D Plan	Taltz in PsO
Express Scripts [®] Part D	Exclusive IL-17A antagonist
Cigna [®] Part D	Exclusive IL-17A antagonist
SilverScript [®] Plans	Exclusive IL-17A antagonist
Wellcare [®] Medicare Plans	Exclusive IL-17A antagonist
Aetna [™] Medicare Plans	Exclusive IL-17A antagonist

Source: Data on File. Lilly USA, LLC. DOF-IX-US-0249, DOF-IX-US-0270 as of 09/2020, and is subject to change without notice by a health plan or state. Please contact the plan or state for the most current information. DEFINITION OF COVERAGE: on formulary, but may be subject to restrictions, step edits, tiering, prior authorizations.

Please see additional formulary plan information on next page.

Taltz is **indicated** for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy, adults with active psoriatic arthritis (PsA), adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

Taltz is **contraindicated** in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Please see [Important Safety Information](#) on next page and accompanying full [Prescribing Information](#) and [Medication Guide](#). See [Instructions for Use](#) included with the device.



Important Safety Information

CONTRAINDICATIONS

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Infections

Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity

Serious hypersensitivity reactions, including angioedema and urticaria (each $\leq 0.1\%$), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Additional Formulary Information

This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.

This list may not be an exhaustive list of all plans in your area and the coverage of other plans in your area may vary.

Employers and employer groups may also offer additional benefit designs which may be different than described.

Subject to contractual limitations, this list is not an exhaustive list of plans. If you do not see a specific Medicare Part D plan, please visit www.medicare.gov.

The company/plan names listed do not imply their endorsement of Lilly USA, LLC or the product(s) referenced.

Lilly USA, LLC does not endorse any particular plan. Other product and company names mentioned herein are the trademarks of their respective owners.

Reference:

1. Data on File. Lilly USA, LLC. DOF-IX-US-0243.

Taltz[®] is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries and affiliates.

Taltz Together[™] is a trademark of Eli Lilly and Company.

Other company and product names are trademarks of their respective owners.

PP-IX-US-4553 12/2020 ©Lilly USA, LLC 2020. All rights reserved.

Inflammatory Bowel Disease

Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations

Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 1\%$) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please see accompanying full [Prescribing Information](#) and [Medication Guide](#). See [Instructions for Use](#) included with the device.

IX HCP ISI 07MAY2020